{
    "2021-03-08": [
        [
            {
                "time": "",
                "original_text": "医药周报：坚守具备估值安全垫、业绩增长确定性高的二线龙头",
                "features": {
                    "keywords": [
                        "医药",
                        "估值安全垫",
                        "业绩增长",
                        "二线龙头"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "东吴证券 - 医药生物行业跟踪周报：医药板块估值有多贵？哪些估值贵【行业研究】",
                "features": {
                    "keywords": [
                        "东吴证券",
                        "医药生物",
                        "估值",
                        "行业研究"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "平安证券 - 生物医药行业周报：《政府工作报告》发布，将进一步深化医药卫生体制改革【行业研究】",
                "features": {
                    "keywords": [
                        "平安证券",
                        "生物医药",
                        "政府工作报告",
                        "医改"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业报告：创新药企商业化能力的再思考",
                "features": {
                    "keywords": [
                        "医药生物",
                        "创新药企",
                        "商业化能力"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}